<DOC>
	<DOC>NCT02761642</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of subcutaneous (SC) r-HuEPO in anemic participants with breast cancer undergoing chemotherapy.</brief_summary>
	<brief_title>A Study of Recombinant Human Erythropoietin Beta (r-HuEPO) (NeoRecormon) in Anemic Participants With Breast Cancer Undergoing Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult female participants with histological diagnosis of breast cancer Any type of chemotherapy planned for greater than or equal to (&gt;/=) 9 weeks Hemoglobin less than (&lt;) 11 grams per deciliter (g/dL) Participants able to receive iron supplement, if necessary Known or suspected contraindications to rHuEPO Pregnancy or lactation period Diagnosis of anemia only due to irondeficiency Diagnosis of thalassemic syndromes Epilepsy and/or cerebral metastasis Blood transfusion or treatment with any erythropoietic agent within 4 weeks before study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>